Gilead Sciences has shored up its position in cell therapies for cancer with a deal to acquire Arcellx, a company it has been ...

CagriSema was submitted for FDA approval last December as a treatment for obesity last December, with a decision due later ...

Among the issues highlighted by patients in the study were lengthy waits for appointments, obstacles to changing or ...

Keller’s goal is for Daichii-Sankyo’s portfolio of two approved ADCs to be up to four by 2030, with approvals for IDXD as well as raludotatug deruxtecan (RDXD). The idea is to extract as much value ...

Many of the UK’s most promising life sciences innovations continue to face persistent funding challenges, made worse by an increasingly volatile global trade environment. Without sustained investment, ...

As reported in January this year, the United States Centers for Medicare & Medicaid Services (CMS) rolled out $10 billion in rural health funding to states in what was the first distribution of ...

The combination of AstraZeneca's Calquence and AbbVie/Roche's Venclexta has become the first all-oral, fixed-duration regimen for patients with newly-diagnosed chronic lymphocytic leukaemia (CLL) in ...

The imposition of new levies evaporated any hope that SCOTUS' decision would give some respite from the relentless disruption resulting from Trump's 'Liberation Day' tariffs, which were imposed in ...

Earlier this week, NHS England said that production problems at German company Heraeus Medical – which is the main supplier ...

The FDA plans to adopt a new policy that will do away with the default requirement to base regulatory filings for new ...

The agreement gives MSD (known as Merck & Co in the US and Canada) access to the Mayo Clinic Platform architecture – which ...

The three-year study – led by mental health data science company Akrivia Health in partnership with Cardiff University – will ...